{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T22:43:51Z","timestamp":1777934631685,"version":"3.51.4"},"reference-count":29,"publisher":"SAGE Publications","issue":"3","license":[{"start":{"date-parts":[[2023,12,19]],"date-time":"2023-12-19T00:00:00Z","timestamp":1702944000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Oncol Pharm Pract"],"published-print":{"date-parts":[[2024,4]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The plasma cell malignancy, multiple myeloma (MM), remains incurable despite advanced treatment protocols. Overexpression of Bcl-2 (an anti-apoptotic protein), in MM harboring the translocation (11;14), contributes to resistance to prior therapy. Venetoclax, a selective oral inhibitor of BCL-2 is a novel agent that shows promise as a therapeutic agent.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>The objective of this systematic review is to address how the use of venetoclax, alone or as a combination regimen, contributed to the treatment of patients with t(11:14) positive relapsed\/refractory multiple myeloma (RRMM).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data sources<\/jats:title>\n                    <jats:p>This systematic review was conducted in accordance to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines and was done on 5th June 2022. A literature search was conducted on PubMed and Scopus, 145 articles were screened and 10 studies were included. Risk of bias assessment was performed using the Methodological Index for Non-Randomized Studies (MINORS) criteria.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data summary<\/jats:title>\n                    <jats:p>Across the studies reviewed, a total of 311 patients were identified with t(11;14) positive RRMM. The overall response rate achieved ranged between 33% and 95.5%. Furthermore, the use of venetoclax has exhibited a favorable adverse effect profile. Side effects included hematological side effects, nausea, vomiting, and diarrhea.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Venetoclax demonstrates promising results. When given with drugs like dexamethasone, daratumumab and carfilzomib, a synergistic effect is seen in treating translocation (11:14) positive relapsed\/refractory MM. The use of venetoclax in clinical practice can potentially improve outcomes and quality of life in RRMM patients, and future research should continue to explore this promising treatment option.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/10781552231218999","type":"journal-article","created":{"date-parts":[[2023,12,19]],"date-time":"2023-12-19T12:01:41Z","timestamp":1702987301000},"page":"552-561","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":1,"title":["Use of venetoclax in t(11;14) positive relapsed\/refractory multiple myeloma: A systematic review"],"prefix":"10.1177","volume":"30","author":[{"given":"Wardah Javed","family":"Khan","sequence":"first","affiliation":[{"name":"Demonstrator (Teaching Faculty) Pharmacology and Therapeutics, Northwest School of Medicine, Peshawar, Pakistan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mubeen","family":"Ali","sequence":"additional","affiliation":[{"name":"Demonstrator (Teaching Faculty) Pharmacology and Therapeutics, Northwest School of Medicine, Peshawar, Pakistan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sana","family":"Hashim","sequence":"additional","affiliation":[{"name":"Batterjee Medical College, Jeddah, Saudi Arabia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huma","family":"Nawaz","sequence":"additional","affiliation":[{"name":"Demonstrator (Teaching Faculty) Pharmacology and Therapeutics, Northwest School of Medicine, Peshawar, Pakistan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Syeda Nafeesa","family":"Hashim","sequence":"additional","affiliation":[{"name":"Batterjee Medical College, Jeddah, Saudi Arabia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1257-7934","authenticated-orcid":false,"given":"Danish","family":"Safi","sequence":"additional","affiliation":[{"name":"Hematology and Oncology, West Virginia University Cancer Center, Morgantown, WV, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arslan","family":"Inayat","sequence":"additional","affiliation":[{"name":"Internal Medicine, HSHS St Mary's Hospital, Decatur, IL, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2023,12,19]]},"reference":[{"key":"bibr1-10781552231218999","doi-asserted-by":"publisher","DOI":"10.3389\/pore.2022.1610276"},{"key":"bibr2-10781552231218999","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26083"},{"key":"bibr3-10781552231218999","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.00443"},{"key":"bibr4-10781552231218999","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020004146"},{"key":"bibr5-10781552231218999","doi-asserted-by":"publisher","DOI":"10.1016\/j.exphem.2018.02.002"},{"key":"bibr6-10781552231218999","volume":"372","author":"Page MJ","year":"2021","journal-title":"Br Med J"},{"key":"bibr7-10781552231218999","doi-asserted-by":"publisher","DOI":"10.1016\/j.infsof.2022.106908"},{"key":"bibr8-10781552231218999","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404284"},{"key":"bibr9-10781552231218999","doi-asserted-by":"publisher","DOI":"10.1046\/j.1445-2197.2003.02748.x"},{"key":"bibr10-10781552231218999","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26207"},{"key":"bibr11-10781552231218999","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-020-00397-w"},{"key":"bibr12-10781552231218999","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30525-8"},{"key":"bibr13-10781552231218999","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-021-04555-3"},{"key":"bibr14-10781552231218999","doi-asserted-by":"crossref","unstructured":"Kambhampati S, Galligan D, Huang CY, et al. A single-center retrospective cohort analysis of venetoclax in relapsed\/refractory multiple myeloma.\n                      Leuk Lymphoma\n                      2020; 61: 1211\u20131219. DOI: 101080\/1042819420191709835","DOI":"10.1080\/10428194.2019.1709835"},{"key":"bibr15-10781552231218999","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26269"},{"key":"bibr16-10781552231218999","first-page":"2950","volume":"12","author":"Bal S","year":"2022","journal-title":"Am J Cancer Res"},{"key":"bibr17-10781552231218999","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2018.07.034"},{"key":"bibr18-10781552231218999","doi-asserted-by":"publisher","DOI":"10.3390\/antib12020038"},{"key":"bibr19-10781552231218999","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2011.196"},{"key":"bibr20-10781552231218999","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2015.350"},{"key":"bibr21-10781552231218999","unstructured":"Venetoclax Plus Dexamethasone Shows Activity in Multiple Myeloma - The ASCO Post, https:\/\/ascopost.com\/issues\/february-25-2020\/venetoclax-plus-dexamethasone-shows-activity-in-multiple-myeloma\/ (accessed 17 July 2023)."},{"key":"bibr22-10781552231218999","doi-asserted-by":"publisher","DOI":"10.3390\/jpm11060463"},{"key":"bibr23-10781552231218999","doi-asserted-by":"publisher","DOI":"10.1038\/s41420-022-01009-1"},{"key":"bibr24-10781552231218999","doi-asserted-by":"publisher","DOI":"10.1111\/cas.15073"},{"key":"bibr25-10781552231218999","doi-asserted-by":"publisher","DOI":"10.1358\/dot.2021.57.10.3313853"},{"key":"bibr26-10781552231218999","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-022-02287-3"},{"key":"bibr27-10781552231218999","doi-asserted-by":"publisher","DOI":"10.6004\/jadpro.2022.13.4.4"},{"key":"bibr28-10781552231218999","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(10)70261-8"},{"key":"bibr29-10781552231218999","doi-asserted-by":"publisher","DOI":"10.1097\/CAD.0000000000001350"}],"container-title":["Journal of Oncology Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552231218999","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10781552231218999","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552231218999","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T02:29:19Z","timestamp":1777688959000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10781552231218999"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,19]]},"references-count":29,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["10.1177\/10781552231218999"],"URL":"https:\/\/doi.org\/10.1177\/10781552231218999","relation":{},"ISSN":["1078-1552","1477-092X"],"issn-type":[{"value":"1078-1552","type":"print"},{"value":"1477-092X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,19]]}}}